Sutro Biopharma, Inc. (STRO)Healthcare | Biotechnology | South San Francisco, United States | NasdaqGM
11.03 USD
-2.25
(-16.943%) ⇩
(Oct. 13, 2026, 1:32 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 10:49 a.m. EDT
The investment case here is fundamentally broken. The company is hemorrhaging cash with negative gross margins and operating cash flow, while revenue has collapsed by nearly 85% year-over-year. The balance sheet is a liability with negative book value, and the stock has erased over 94% of its value over the last seven years. While analysts have recently upgraded revenue forecasts, the market has already punished this stock severely, evidenced by the crushing 75% drop in the trailing twelve months. There is no dividend to provide a floor, and the options market is silent on upside, with heavy put interest sitting far out of the money. This is a deep value trap where the business model appears to be failing, making it a dangerous hold regardless of the theoretical potential of future drug candidates. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.268761 |
| AutoETS | 0.273377 |
| AutoARIMA | 0.276818 |
| MSTL | 0.278612 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 34% |
| H-stat | 14.44 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.225 |
| Excess Kurtosis | -1.24 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 3.915 |
| Market Cap | 182,890,304 |
| Forward P/E | -1.78 |
| Beta | 1.50 |
| Website | https://www.sutrobio.com |
As of Oct. 10, 2026, 10:49 a.m. EDT: Options activity shows a distinct lack of bullish positioning. Call open interest is negligible across all expirations, with zero in-the-money volume. Conversely, put open interest is concentrated significantly out-of-the-money (OTM) at strikes like $30, suggesting speculative hedging or a 'long shot' bet on a massive recovery rather than a near-term bounce. The implied volatility is extremely low, indicating a market that has priced out any meaningful movement in either direction, leaving the stock effectively dead money for active traders.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.65999997 |
| Address1 | 111 Oyster Point Boulevard |
| All Time High | 283.0 |
| All Time Low | 5.2 |
| Ask | 31.7 |
| Ask Size | 2 |
| Audit Risk | 4 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 251,600 |
| Average Daily Volume3 Month | 292,262 |
| Average Volume | 292,262 |
| Average Volume10Days | 251,600 |
| Beta | 1.495 |
| Bid | 18.57 |
| Bid Size | 2 |
| Board Risk | 5 |
| Book Value | -6.233 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 11.03 |
| Current Ratio | 3.32 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 13.185 |
| Day Low | 11.03 |
| Display Name | Sutro Biopharma |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,741,899,600 |
| Earnings Call Timestamp Start | 1,741,899,600 |
| Earnings Timestamp End | 1,755,298,800 |
| Earnings Timestamp Start | 1,754,953,200 |
| Ebitda | -125,795,000 |
| Ebitda Margins | -2.75251 |
| Enterprise To Ebitda | -0.53 |
| Enterprise To Revenue | 1.458 |
| Enterprise Value | 66,634,952 |
| Eps Current Year | -7.77 |
| Eps Forward | -6.2125 |
| Eps Trailing Twelve Months | -17.28 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 650 553 9659 |
| Fifty Day Average | 19.0672 |
| Fifty Day Average Change | -8.0372 |
| Fifty Day Average Change Percent | -0.4215197 |
| Fifty Two Week Change Percent | 66.0 |
| Fifty Two Week High | 43.85 |
| Fifty Two Week High Change | -32.82 |
| Fifty Two Week High Change Percent | -0.7484607 |
| Fifty Two Week Low | 7.15 |
| Fifty Two Week Low Change | 3.8799996 |
| Fifty Two Week Low Change Percent | 0.54265726 |
| Fifty Two Week Range | 7.15 - 43.85 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,538,055,000,000 |
| Float Shares | 10,763,170 |
| Forward Eps | -6.2125 |
| Forward P E | -1.7754526 |
| Free Cashflow | -100,756,000 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 128 |
| Fullday Change | -2.25 |
| Fullday Change Percent | -16.942772 |
| Fullday Price | 11.03 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | -2.1671 |
| Gross Profits | -99,041,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02258 |
| Held Percent Institutions | 0.98914003 |
| Implied Shares Outstanding | 16,581,171 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,764,720,000 |
| Last Split Factor | 1:10 |
| Long Business Summary | Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, endometrial cancer, and bladder cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease in adults and adults and infants; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers. Sutro Biopharma, Inc. has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California. |
| Long Name | Sutro Biopharma, Inc. |
| Market | us_market |
| Market Cap | 182,890,304 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_38768157 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -180,636,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 267,454,288 |
| Number Of Analyst Opinions | 13 |
| Open | 13.11 |
| Operating Cashflow | -145,172,992 |
| Operating Margins | -3.0172799 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 650 881 6500 |
| Previous Close | 13.28 |
| Price Eps Current Year | -1.4195623 |
| Price Hint | 2 |
| Price To Book | -1.7696134 |
| Price To Sales Trailing12 Months | 4.001801 |
| Profit Margins | 0.0 |
| Quick Ratio | 3.216 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.42857 |
| Region | US |
| Regular Market Change | -2.25 |
| Regular Market Change Percent | -16.942772 |
| Regular Market Day High | 13.185 |
| Regular Market Day Low | 11.03 |
| Regular Market Day Range | 11.03 - 13.185 |
| Regular Market Open | 13.11 |
| Regular Market Previous Close | 13.28 |
| Regular Market Price | 11.03 |
| Regular Market Time | 1,791,912,736 |
| Regular Market Volume | 200,759 |
| Return On Assets | -0.36081 |
| Revenue Growth | -0.846 |
| Revenue Per Share | 3.915 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 16,581,171 |
| Shares Percent Shares Out | 0.1114 |
| Shares Short | 1,847,453 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 1,809,482 |
| Short Name | Sutro Biopharma, Inc. |
| Short Percent Of Float | 0.1118 |
| Short Ratio | 5.93 |
| Source Interval | 15 |
| State | CA |
| Symbol | STRO |
| Target High Price | 61.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 47.23077 |
| Target Median Price | 50.0 |
| Total Cash | 164,346,000 |
| Total Cash Per Share | 9.912 |
| Total Debt | 10,783,000 |
| Total Revenue | 45,702,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -17.28 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 23.11615 |
| Two Hundred Day Average Change | -12.08615 |
| Two Hundred Day Average Change Percent | -0.52284443 |
| Type Disp | Equity |
| Volume | 200,759 |
| Website | https://www.sutrobio.com |
| Zip | 94,080 |